$QBIO News - Q BioMed Inc. and Mannin Research Inc Sign Definitive License Agreement

Platform technology well positioned to be a First-In-Class molecule for the treatment of glaucoma as well as cystic kidney disease and others.

NEW YORK, - (http://www.financialnewsmedia.com News Alert) - Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc.



Mannin Research Inc., is a biotechnology company leading the development of a new class of vascular therapeutics. The drug development program at Mannin is led by Mannin\'s Chief Scientific Officer, Dr. Susan E. Quaggin, Chief of the Division of Nephrology and Director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago.



Utilizing a proprietary research platform, only recently published (September 2014) in the Journal of Clinical Investigations, this technology is addressing the need for a new class of drugs to treat diseases such as glaucoma and Cystic Kidney disease. Our primary target indication is for a first-in-class therapeutic eye-drop for the treatment of glaucoma in adults and children.



The global market for glaucoma therapeutics is one of the largest segments of the $23 billion global ophthalmology market. There are 60 million people worldwide suffering from glaucoma. It is projected that the total population suffering from glaucoma will grow to 80 million by 2020 (W.H.O 2010). The lead candidate, MAN-01, will address this market as a first-in-class drug that is designed to treat abnormal vessels within the eye, thereby treating glaucoma at its root causes.



There is no cure for glaucoma and new therapeutics are highly sought after. Current therapies and surgical procedures are not optimally effective, are painful and not well tolerated by patients.



Intra-Ocular Pressure (IOP) is caused by abnormal flow of clear fluid within the eye, causing irreversible damage to the eye, ultimately leading to blindness. A specialized blood vessel, the \'Schlemm\'s canal\' is the major drainage pathway for fluid to escape from the front of the eye. Glaucoma can occur when this canal is either blocked during the patient\'s lifetime or impaired from a birth defect, resulting in a small or absent Schlemm\'s canal.